JP2019517542A5 - - Google Patents

Info

Publication number

JP2019517542A5

JP2019517542A5 JP2018563848A JP2018563848A JP2019517542A5 JP 2019517542 A5 JP2019517542 A5 JP 2019517542A5 JP 2018563848 A JP2018563848 A JP 2018563848A JP 2018563848 A JP2018563848 A JP 2018563848A JP 2019517542 A5 JP2019517542 A5 JP 2019517542A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

metformin

linagliptin

composition according

oral administration

Prior art date

2017-06-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 19
• 239000008194 pharmaceutical composition Substances 0.000 claims 19
• LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 12
• 229960002397 linagliptin Drugs 0.000 claims 12
• 229960003105 metformin Drugs 0.000 claims 12
• 229960004329 metformin hydrochloride Drugs 0.000 claims 7
• OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims 7
• 206010012601 diabetes mellitus Diseases 0.000 claims 5
• 239000000203 mixture Substances 0.000 claims 5
• 239000004480 active ingredient Substances 0.000 claims 4
• 108060006698 EGF receptor Proteins 0.000 claims 3
• 230000024924 glomerular filtration Effects 0.000 claims 3
• 230000002641 glycemic effect Effects 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• 238000013268 sustained release Methods 0.000 claims 3
• 239000012730 sustained-release form Substances 0.000 claims 3
• 230000009977 dual effect Effects 0.000 claims 2
• 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
• 238000002560 therapeutic procedure Methods 0.000 claims 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
• 102000004877 Insulin Human genes 0.000 claims 1
• 108090001061 Insulin Proteins 0.000 claims 1
• 229940100389 Sulfonylurea Drugs 0.000 claims 1
• 239000013543 active substance Substances 0.000 claims 1
• 239000003472 antidiabetic agent Substances 0.000 claims 1
• 229940125396 insulin Drugs 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000006186 oral dosage form Substances 0.000 claims 1
• 238000009097 single-agent therapy Methods 0.000 claims 1
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1